Neurological opportunistic infections and neurological immune reconstitution syndrome: Impact of one decade of highly active antiretroviral treatment in a tertiary hospital

HIV Medicine

Volumn 14, Issue 1, 2013, Pages 21-30

  Riveiro Barciela, M ^a   Falco V ^a   Burgos, J ^a   Curran, A ^a   Van den Eynde, E ^a   Navarro, J ^a   Villar del Saz, S ^a   Ocana I ^a   Ribera, E ^a   Crespo, M ^a   Pahissa, A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cerebral toxoplasmosis; Cryptococcal meningitis; Immune reconstitution inflammatory syndrome; Progressive multifocal leukoencephalopathy; Tuberculous meningitis

Indexed keywords

ANTIRETROVIRUS AGENT; STEROID;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCAL MENINGITIS; DEVELOPED COUNTRY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SPAIN; SURVIVAL TIME; TERTIARY HEALTH CARE; TOXOPLASMOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOUS MENINGITIS; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CENTRAL NERVOUS SYSTEM DISEASES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MALE; MIDDLE AGED; SPAIN;

EID: 84870570944     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01033.x     Document Type: Article

References (44)

1. Mocroft A, Ledergerber B, Katlama C etal. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
2. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA 1998; 280: 72-77.
3. Michelet C, Arvieux C, Francois C etal. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12: 1815-1822.
4. Lortholary O, Fontanet A, Mémain N etal. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19: 1043-1049.
5. Abgrall S, Rabaud C, Costagliola D, Clinical Epidemiology Group of the French Hospital Database of HIV. Incidence and risk factors for toxoplasmic encephalitis in human inmunodeficiency virus-infected patients before and during the highly active antirretroviral therapy era. Clin Infect Dis 2001; 33: 1747-1755.
6. UK Collaborative HIV Cohort (CHIC) Study Steering Committee, Garvey L, Winston A, Walsh J etal. HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 2011; 18: 527-534.
7. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC etal. Immune reconstitution inflammatory syndrome. Emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81: 213-227.
8. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-1627.
9. Bicanic T, Meintjes G, Rebe K etal. Immune reconstitutions inflammatory syndrome in HIV-associated cryptococcal meningitis: a prostective study. J Acquir Immune Defic Syndr 2009; 51: 130-134.
10. Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr Opin HIV AIDS 2008; 3: 438-445.
11. Shelburne SA, Visnegarwala F, Darcourt J etal. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretrovirral therapy. AIDS 2005; 19: 399-406.
12. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answer, more questions. J Antimicrob Chemother 2006; 57: 167-170.
13. Makadzange AT, Ndhlovy CE, Takarinda K etal. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in Sub-Saharan Africa. Clin Infect Dis 2010; 50: 1532-1538.
14. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 2009; 72: 1458-1464.
15. Portegies P, Solod L, Cinque P etal. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol 2004; 11: 297-304.
16. Mamidi A, DeSimone JA, Pomerantz RJ. Central nervous system infections in individuals with HIV-1 infection. J Neurovirol 2002; 8: 158-167.
17. Falcó V, Olmo M, Del Saz SV etal. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observacional multicenter study. J Acquir Immune Defic Syndr 2008; 49: 26-31.
18. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 215-261.
19. Johnson T, Nath A. Neurological complications of immune reconstitution in HIV-infected populations. Ann N Y Acad Sci 2010; 1184: 106-120.
20. Palella FJ Jr, Delaney KM, Moorman AC etal. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study investigators. N Engl J Med 1998; 338: 853-860.
21. Sacktor N, Lyles RH, Skolasky R etal. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort study, 1990-1998. Neurology 2001; 56: 257-260.
22. Kaplan JE, Hanson D, Dworkin MS etal. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30: S5-14.
23. Grabar S, Lanoy E, Allavena C etal. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008; 9: 246-256.
24. Engsig FN, Hansen AB, Omland LH etal. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199: 77-83.
25. Cinque P, Pierotti C, Viganò MG etal. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7: 358-363.
26. Antinori A, Cingolani A, Lorenzini P etal. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative NeuroAIDS (IRINA). J Neurovirol 2003; 9: 47-53.
27. Cinque P, Bossolasco S, Brambilla AM etal. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurolovirol 2003; 9: 73-80.
28. Albrecht H, Hoffmann C, Degen O etal. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998; 12: 1149-1154.
29. Khanna N, Elzi L, Mueller NJ etal. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV cohort study. Clin Infect Dis 2009; 48: 1459-1466.
30. Hall CD, Dafni U, Simpson D etal. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 1998; 338: 1345-1351.
31. Berenguer J, Miralles P, Arrizabalaga J etal. Clinical course and prognosis factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36: 1047-1052.
32. Wyen C, Hoffmann C, Schmeiβer N etal. Progressive multifocal leukoencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004; 37: 1263-1268.
33. Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O. The prevalence and risk of immune reconstitution restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005; 6: 140-143.
34. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42: 418-427.
35. Murdoch DM, Venter WD, Feldman C, Van Die A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22: 601-610.
36. Sungkanuparph S, Filler SG, Chetchotisakd P etal. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis 2009; 49: 931-934.
37. Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatments options. AIDS Res Ther 2007; 8: 4-9.
38. Meintjes G, Rangaka MX, Maartens G etal. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009; 48: 667-676.
39. Breton G, Duval X, Estellat C etal. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39: 1709-1712.
40. Shelburne SA 3rd, Darcourt J, Clinton White JA etal. The role of immune reconstitution inflammatory syndrome in AIDS-related cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 1049-1052.
41. Cooney EL. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 224-233.
42. Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007; 46: 456-462.
43. Abdool Karim SS, Naidoo K, Grobler A etal. Timing of initiation of antiretroviral drugs during Tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
44. Castelnuovo B, Manabe YC, Kiragga A etal. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009; 49: 965-972.